Amyloidosis: Novel Treatments Could Improve Poor Outcomes

Feb 19, 2026

Isatuximab Demonstrated Promising Efficacy in R/R Light Chain Amyloidosis

Read more

Feb 19, 2026

A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Read more

Feb 19, 2026

Clinical trial criteria exclude over 40% of real-world patients with AL amyloidosis

Read more

Feb 19, 2026

First 23-Patient Safety and Efficacy Data from Nexicart-2, the First U.S. Trial of CAR-T in R/R Light Chain (AL) Amyloidosis, Nxc-201

Read more

Feb 18, 2026

Advances in the Diagnosis and Disease-Modifying Management of Transthyretin Amyloid Cardiomyopathy: A Narrative Review

Read more

Feb 18, 2026

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real‐world patients

Read more

Feb 17, 2026

ATTR-CM May Be Associated With Reduced Risk of Alzheimer Disease

Read more

Feb 14, 2026

Emerging Pharmacological Strategies for Cardiac Amyloidosis: A Qualitative Analysis of Interventional Clinical Trials Registered on ClinicalTrials.Gov

Read more

Feb 13, 2026

Wild-type transthyretin cardiac amyloidosis: the journey to diagnosis in the Czech Republic

Read more

Feb 12, 2026

First Clinical Experience with the Transthyretin Amyloidosis-Quality of Life Questionnaire (ATTR-QOL): Associations with Clinical Characteristics and Established Patient-Reported Outcomes

Read more

Subscribe to